The molecular subtype distribution was as follows: 44.5% of cases Luminal A, 31.4% Luminal B, 19.9% HER2-positive, and 4.2% triple-negative breast cancer (TNBC). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.